Ligand Pharmaceuticals (NSDQ:LGND) said this week that it’s getting into the medical device arena with the nearly $18 million acquisition of multiple tissue repair assets from CorMatrix. San Diego-based Ligand said it paid $17.5 million for synthetic royalties on existing extracellular matrix products, including the CanGaroo ECM envelope for implantable electronic devices, and the right […]